| 2025 | 2024 | |||
|---|---|---|---|---|
| Gross margin | -528,2 k € | -135.0% | -224,8 k € | |
| EBITDA | -528,7 k € | -134.4% | -225,6 k € | |
| Operating profit | -2,6 M € | -29.9% | -2,0 M € | |
| Profit/loss | -2,5 M € | -37.8% | -1,8 M € | |
| Equity | 3,6 M € | -41.2% | 6,0 M € | |
| Total assets | 3,9 M € | -36.8% | 6,1 M € | |
| Cash | 2,7 M € | -43.1% | 4,8 M € | |
| Debts | 315,8 k € | +286.6% | 81,7 k € | |
Source: Belgian Official Gazette
Public limited company · Gent · incorporated on 13/11/2023
Public limited company loss-making in the latest fiscal year. Cash position declining (-43.1%).
Acceptable counterparty for a moderate engagement. Require 2 fiscal years of detailed accounts before any significant exposure. The abridged model hides revenue.
Key indicators
Tanai Therapeutics is a Public limited company incorporated in 2023. Its main activity is: Research and experimental development on natural sciences and engineering. Its registered office is in Gent.